IceCure Medical Ltd. reported fourth‑quarter 2025 revenue of $1.3 million, a 9% increase from $1.2 million in the same period last year, and full‑year revenue of $3.4 million, up 3% from $3.3 million in 2024. The company posted a net loss of $15.06 million for the year, slightly narrower than the $15.32 million loss reported in 2024. EPS for the quarter was $-0.06, missing the consensus estimate of $-0.04 by $0.02 and the prior‑year estimate of $-0.05 by $0.01.
Gross margin for the full year contracted to 36% from 44% in 2024, reflecting higher cost of goods sold driven by increased production of the ProSense cryoablation system and higher raw‑material costs. The margin decline indicates pricing pressure and the need for cost discipline as the company scales.
The results were bolstered by the FDA clearance of the ProSense system for low‑risk breast cancer in October 2025 and the American Society of Breast Surgeons recommendation in March 2026. These regulatory milestones have accelerated adoption, leading to a 30‑site expansion for the post‑marketing study and a growing installation footprint in the United States and abroad.
Management reiterated its guidance for 2026, maintaining a revenue outlook of $3.5 million to $3.6 million and a net loss of $15 million to $16 million. The company emphasized continued investment in the post‑marketing study and international regulatory submissions, while noting that margin compression will persist until the product line matures and cost efficiencies are realized.
The earnings miss on EPS underscores the company’s ongoing profitability challenges, but the modest revenue growth and regulatory approvals signal a positive trajectory for the ProSense platform. Investors will likely focus on the company’s ability to convert increased sales volume into margin improvement and to achieve profitability as the market for minimally invasive breast cancer treatment expands.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.